In the frantic rush to the clinic with various IO-IO combinations, many people seem to have forgotten that these have an increased risk of failure than say, combining one IO molecule with chemotherapy.
This risk can take the form of increased toxicities, as well as lack of efficacy, especially if you are giving an unknown therapy instead of one that is known to be effective in controlling the tumour.
We look at a tale of two cities in lung cancer; there are some interesting lessons to be learned here…
To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
Killer T cells surround a cancer cell Source: Alex Ritter, Jennifer Lippincott Schwartz & Gillian Griffiths, NIH
With a series of high profile phase 3 cancer immunotherapy combination trials expected to readout throughout 2018, what can we expect given the promise they may offer?
While many people tend to assume that a doublet should produce more efficacy than monotherapy, this isn’t always the case and there’s also the risk of increased toxicities.
That said, are there any hints and learnings we can garner from preclinical and clinical research that might help us assess some of the underlying challenges inherent in these randomised controlled trials?
I say yes there are and here we take a look at a couple of important indicators that may help understand what to expect ahead of time.
To learn more from our conference commentary and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.